Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY

NET SALES FROM CONTINUING OPERATIONS

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2005																					2006													% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Net Sales
Pharmaceuticals	$	3,578		$	3,886		$	7,464		$	3,778		$	11,242		$	4,012		$	15,254		$	3,700		$	3,859		$	7,559						-1	%	1	%
US Pharmaceuticals		1,767			2,084			3,851			2,069			5,920			2,220			8,140			2,064			2,197			4,261						5	%	11	%
Primary Care		1,258			1,539			2,797			1,486			4,283			1,653			5,936			1,409			1,441			2,850						-6	%	2	%
Oncology/Virology		348			345			693			370			1,063			391			1,454			419			458			877						33	%	27	%
Neuroscience		161			200			361			213			574			176			750			231			280			511						40	%	42	%
Immunoscience		—			—			—			—			—			—			—			5			18			23						—		—
Latin America/Canada		258			306			564			285			849			325			1,174			288			303			591						-1	%	5	%
Europe and Middle East Medicines		1,201			1,112			2,313			1,030			3,343			1,053			4,396			1,024			1,000			2,024						-10	%	-12	%
Asia/Pacific Medicines		299			329			628			342			970			354			1,324			279			320			599						-3	%	-5	%
Nutritionals		526			548			1,074			547			1,621			584			2,205			565			582			1,147						6	%	7	%
Other Health Care		428			455			883			442			1,325			423			1,748			411			430			841						-5	%	-5	%
ConvaTec		228			247			475			250			725			267			992			230			262			492						6	%	4	%
Medical Imaging		145			151			296			150			446			156			602			181			168			349						11	%	18	%
Consumer Medicines		55			57			112			42			154			—			154			—			—			—						-100	%	-100	%
Total Company	$	4,532		$	4,889		$	9,421		$	4,767		$	14,188		$	5,019		$	19,207		$	4,676		$	4,871		$	9,547						—		1	%
	2005																					2006													Basis Point Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
% of Total Sales
Pharmaceuticals		79.0	%		79.5	%		79.2	%		79.3	%		79.2	%		79.9	%		79.4	%		79.1	%		79.2	%		79.2	%					(30	)	—
US Pharmaceuticals		39.0	%		42.6	%		40.9	%		43.4	%		41.7	%		44.2	%		42.4	%		44.1	%		45.1	%		44.6	%					250		370
Primary Care		27.8	%		31.4	%		29.7	%		31.2	%		30.2	%		32.9	%		30.9	%		30.1	%		29.6	%		29.9	%					(180	)	20
Oncology/Virology		7.7	%		7.1	%		7.4	%		7.8	%		7.5	%		7.8	%		7.6	%		9.0	%		9.4	%		9.2	%					230		180
Neuroscience		3.5	%		4.1	%		3.8	%		4.4	%		4.0	%		3.5	%		3.9	%		4.9	%		5.7	%		5.3	%					160		150
Immunoscience		—			—			—			—			—			—			—			0.1	%		0.4	%		0.2	%					40		20
Latin America/Canada		5.7	%		6.3	%		6.0	%		6.0	%		6.0	%		6.5	%		6.1	%		6.2	%		6.2	%		6.2	%					(10	)	20
Europe and Middle East Medicines		26.5	%		22.7	%		24.6	%		21.6	%		23.6	%		21.0	%		22.9	%		21.9	%		20.5	%		21.2	%					(220	)	(340	)
Asia/Pacific Medicines		6.6	%		6.7	%		6.7	%		7.2	%		6.8	%		7.1	%		6.9	%		6.0	%		6.6	%		6.3	%					(10	)	(40	)
Nutritionals		11.6	%		11.2	%		11.4	%		11.5	%		11.4	%		11.7	%		11.5	%		12.1	%		12.0	%		12.0	%					80		60
Other Health Care		9.4	%		9.3	%		9.4	%		9.2	%		9.4	%		8.4	%		9.1	%		8.8	%		8.8	%		8.8	%					(50	)	(60	)
ConvaTec		5.0	%		5.0	%		5.1	%		5.2	%		5.1	%		5.3	%		5.2	%		4.9	%		5.4	%		5.2	%					40		10
Medical Imaging		3.2	%		3.1	%		3.1	%		3.1	%		3.2	%		3.1	%		3.1	%		3.9	%		3.4	%		3.6	%					30		50
Consumer Medicines		1.2	%		1.2	%		1.2	%		0.9	%		1.1	%		—			0.8	%		—			—			—						(120	)	(120	)
Total Company		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%

BRISTOL-MYERS SQUIBB COMPANY

SEGMENT SALES AND COMPOSITION OF CHANGE IN SALES FOR CONTINUING OPERATIONS

FOR THE PERIOD ENDED JUNE 30, 2006

($ in millions)

QUARTER-TO-DATE

	Pharmaceuticals			Nutritionals			ConvaTec			Medical Imaging			Consumer Medicines			Continuing Operations
Price Increases/(Decreases)		3	%		4	%		-1	%		-1	%		—			3	%
Foreign Exchange		—			1	%		—			—			—			—
Volume		-4	%		1	%		7	%		12	%		-100	%		-3	%
Total Change		-1	%		6	%		6	%		11	%		-100	%		—
Total 2006 Period to Date Sales	$	3,859		$	582		$	262		$	168			—		$	4,871
Total 2005 Period to Date Sales	$	3,886		$	548		$	247		$	151		$	57		$	4,889
YEAR-TO-DATE
	Pharmaceuticals			Nutritionals			ConvaTec			Medical Imaging			Consumer Medicines			Continuing Operations
Price Increases/(Decreases)		4	%		3	%		—			2	%		—			4	%
Foreign Exchange		-1	%		1	%		-3	%		—			—			-1	%
Volume		-2	%		3	%		7	%		16	%		-100	%		-2	%
Total Change		1	%		7	%		4	%		18	%		-100	%		1	%
Total 2006 Period to Date Sales	$	7,559		$	1,147		$	492		$	349			—		$	9,547
Total 2005 Period to Date Sales	$	7,464		$	1,074		$	475		$	296		$	112		$	9,421

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED STATEMENT OF EARNINGS

CONTINUING OPERATIONS

($ in Millions, except per share amounts)

	2005																					2006													% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Net Sales	$	4,532		$	4,889		$	9,421		$	4,767		$	14,188		$	5,019		$	19,207		$	4,676		$	4,871		$	9,547						—		1	%
Cost of products sold		1,367			1,483			2,850			1,483			4,333			1,595			5,928			1,476			1,568			3,044						6	%	7	%
Marketing, selling and administrative		1,183			1,268			2,451			1,286			3,737			1,369			5,106			1,238			1,181			2,419						-7	%	-1	%
Advertising and product promotion		318			365			683			349			1,032			444			1,476			295			352			647						-4	%	-5	%
Research and development		653			649			1,302			669			1,971			775			2,746			750			740			1,490						14	%	14	%
Provision for restructuring and other items, net		3			2			5			(5	)		—			32			32			1			3			4						50	%	-20	%
Litigation (income)/charges, net		124			(26	)		98			(26	)		72			197			269			(21	)		(14	)		(35	)					46	%	-136	%
Gain on sale of business and product asset		—			—			—			(569	)		(569	)		—			(569	)		(200	)		—			(200	)					—		—
Equity in net income of affiliates		(69	)		(87	)		(156	)		(84	)		(240	)		(94	)		(334	)		(93	)		(125	)		(218	)					-44	%	-40	%
Other (income)/expense, net		25			105			130			38			168			(131	)		37			37			56			93						-47	%	-28	%
Total expenses		3,604			3,759			7,363			3,141			10,504			4,187			14,691			3,483			3,761			7,244						—		-2	%
Earnings from Continuing Operations Before Minority Interest and Income Taxes		928			1,130			2,058			1,626			3,684			832			4,516			1,193			1,110			2,303						-2	%	12	%
Provision for income taxes		268			(21	)		247			507			754			178			932			328			256			584						*		136	%
Minority interest, net of taxes		122			160			282			155			437			155			592			151			187			338						17	%	20	%
Earnings from Continuing Operations	$	538		$	991		$	1,529		$	964		$	2,493		$	499		$	2,992		$	714		$	667		$	1,381						-33	%	-10	%
Interest expense on conversion of convertible debt bonds, net of tax		4			5			9			6			15			7			22			8			8			16
Earnings from continuing operations used for diluted earnings per common share calculation	$	542		$	996		$	1,538		$	970		$	2,508		$	506		$	3,014		$	722		$	675		$	1,397
Diluted Earnings per Common Share Continuing Operations**	$	0.27		$	0.50		$	0.78		$	0.49		$	1.27		$	0.26		$	1.52		$	0.36		$	0.34		$	0.70						-32	%	-10	%
Average Common Shares Outstanding - Diluted		1,981			1,984			1,982			1,984			1,983			1,983			1,983			1,988			1,994			1,992						1	%	1	%
Dividends declared per common share	$	0.28		$	0.28		$	0.56		$	0.28		$	0.84		$	0.28		$	1.12		$	0.28		$	0.28		$	0.56						—		—
	2005																					2006													Basis Point Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
% of Net Sales
Gross Margin		69.8	%		69.7	%		69.7	%		68.9	%		69.5	%		68.2	%		69.1	%		68.4	%		67.8	%		68.1	%					(190	)	(160	)
Cost of products sold		30.2	%		30.3	%		30.3	%		31.1	%		30.5	%		31.8	%		30.9	%		31.6	%		32.2	%		31.9	%					190		160
Marketing, selling and administrative		26.1	%		25.9	%		26.0	%		27.0	%		26.3	%		27.3	%		26.6	%		26.5	%		24.2	%		25.3	%					(170	)	(70	)
Advertising and product promotion		7.0	%		7.5	%		7.2	%		7.3	%		7.3	%		8.8	%		7.7	%		6.3	%		7.2	%		6.8	%					(30	)	(40	)
Research and development		14.4	%		13.3	%		13.8	%		14.0	%		13.9	%		15.4	%		14.3	%		16.0	%		15.2	%		15.6	%					190		180
Total expenses		79.5	%		76.9	%		78.2	%		65.9	%		74.0	%		83.4	%		76.5	%		74.5	%		77.2	%		75.9	%					30		(230	)
Earnings from Continuing Operations Before Minority Interest and Provision for Income Taxes		20.5	%		23.1	%		21.8	%		34.1	%		26.0	%		16.6	%		23.5	%		25.5	%		22.8	%		24.1	%					(30	)	230
Earnings from Continuing Operations		11.9	%		20.3	%		16.2	%		20.2	%		17.6	%		9.9	%		15.6	%		15.3	%		13.7	%		14.5	%					(660	)	(170	)
Other Ratios
Effective Tax Rate		28.9	%		-1.9	%		12.0	%		31.2	%		20.5	%		21.4	%		20.6	%		27.5	%		23.1	%		25.4	%
	2005																					2006													% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Other (Income)/Expense, net
Interest expense	$	97		$	73		$	170		$	79		$	249		$	100		$	349		$	116		$	124		$	240						70	%	41	%
Interest income		(45	)		(23	)		(68	)		(28	)		(96	)		(52	)		(148	)		(62	)		(65	)		(127	)					-183	%	-87	%
Foreign exchange transaction (gains)/losses		12			35			47			—			47			11			58			(12	)		23			11						-34	%	-77	%
Other, net		(39	)		20			(19	)		(13	)		(32	)		(190	)		(222	)		(5	)		(26	)		(31	)					*		-63	%
	$	25		$	105		$	130		$	38		$	168		($	131	)	$	37		$	37		$	56		$	93						-47	%	-28	%

* in excess of +/- 200%

** amounts may not calculate due to rounding differences between continuing and discontinued operations.

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE NET SALES FROM CONTINUING OPERATIONS BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2005														2006										% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Total Company	$	4,532	$	4,889	$	9,421	$	4,767	$	14,188	$	5,019	$	19,207	$	4,676	$	4,871	$	9,547					—		1	%
PHARMACEUTICALS		3,578		3,886		7,464		3,778		11,242		4,012		15,254		3,700		3,859		7,559					-1	%	1	%
Cardiovascular		1,712		2,031		3,743		1,935		5,678		2,090		7,768		1,917		1,907		3,824					-6	%	2	%
Plavix		814		968		1,782		980		2,762		1,061		3,823		986		1,145		2,131					18	%	20	%
Pravachol		520		625		1,145		527		1,672		584		2,256		536		323		859					-48	%	-25	%
Avapro/ Avalide		196		258		454		251		705		277		982		233		280		513					9	%	13	%
Coumadin		49		50		99		57		156		56		212		55		55		110					10	%	11	%
Monopril		59		54		113		49		162		46		208		48		49		97					-9	%	-14	%
Virology		430		457		887		440		1,327		450		1,777		468		524		992					15	%	12	%
Reyataz		149		183		332		176		508		188		696		207		236		443					29	%	33	%
Sustiva		173		167		340		170		510		170		680		175		193		368					16	%	8	%
Zerit		59		59		118		51		169		47		216		40		41		81					-31	%	-31	%
Baraclude		—		5		5		2		7		5		12		11		14		25					180	%	*	**
Infectious Diseases		293		261		554		239		793		286		1,079		199		172		371					-34	%	-33	%
Cefzil		82		54		136		48		184		75		259		23		23		46					-57	%	-66	%
Oncology		387		371		758		380		1,138		395		1,533		361		401		762					8	%	1	%
Erbitux		87		98		185		107		292		121		413		138		172		310					76	%	68	%
Taxol		205		186		391		175		566		181		747		147		149		296					-20	%	-24	%
Affective (Psychiatric) Disorders		232		284		516		306		822		267		1,089		323		376		699					32	%	35	%
Abilify**		188		240		428		260		688		224		912		283		324		607					35	%	42	%
EMSAM		—		—		—		—		—		—		—		—		12		12					—		—
Immunoscience		—		—		—		—		—		—		—		5		18		23					—		—
Orencia		—		—		—		—		—		—		—		5		18		23					—		—
Other Pharmaceuticals
Efferalgan		88		55		143		66		209		74		283		68		62		130					13	%	-9	%
NUTRITIONALS		526		548		1,074		547		1,621		584		2,205		565		582		1,147					6	%	7	%
Enfamil		235		250		485		230		715		277		992		237		253		490					1	%	1	%
Enfagrow		50		49		99		54		153		53		206		67		59		126					20	%	27	%
OTHER HEALTH CARE		428		455		883		442		1,325		423		1,748		411		430		841					-5	%	-5	%
CONVATEC		228		247		475		250		725		267		992		230		262		492					6	%	4	%
Ostomy		127		139		266		139		405		145		550		123		141		264					1	%	-1	%
Wound Therapeutics		97		103		200		104		304		112		416		98		107		205					4	%	3	%
MEDICAL IMAGING		145		151		296		150		446		156		602		181		168		349					11	%	18	%
Cardiolite		102		108		210		106		316		100		416		103		105		208					-3	%	-1	%
CONSUMER MEDICINES		55		57		112		42		154		—		154		—		—		—					-100	%	-100	%

** Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

*** In excess of +/- 200%

BRISTOL-MYERS SQUIBB COMPANY

DOMESTIC* NET SALES FROM CONTINUING OPERATIONS BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

																																% Change in U.S. Total Prescription****
	2005														2006													% Change				NPA				NGPS
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr			2nd Qtr			6 Months			3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD
Total Company	$	2,310	$	2,668	$	4,978	$	2,638	$	7,616	$	2,845	$	10,461	$	2,638		$	2,806		$	5,444						5	%	9	%
PHARMACEUTICALS		1,777		2,097		3,874		2,082		5,956		2,234		8,190		2,076			2,205			4,281						5	%	11	%
Cardiovascular		1,080		1,377		2,457		1,328		3,785		1,496		5,281		1,341			1,330			2,671						-3	%	9	%
Plavix		673		823		1,496		833		2,329		906		3,235		850			988			1,838						20	%	23	%	14	%	14	%	13	%	13	%
Pravachol		258		353		611		297		908		366		1,274		302			128			430						-64	%	-30	%	-58	%	-37	%	-59	%	-38	%
Avapro/ Avalide		102		157		259		147		406		168		574		139			167			306						6	%	18	%	4	%	5	%	2	%	3	%
Coumadin		42		42		84		49		133		50		183		47			46			93						10	%	11	%	-21	%	-23	%	-21	%	-25	%
Monopril		3		2		5		1		6		3		9		2			1			3						-50	%	-40	%	-54	%	-55	%	-54	%	-55	%
Virology		231		231		462		239		701		244		945		259			270			529						17	%	15	%
Reyataz		92		98		190		105		295		110		405		119			122			241						24	%	27	%	18	%	19	%	18	%	17	%
Sustiva		103		97		200		101		301		102		403		108			115			223						19	%	12	%	7	%	5	%	6	%	5	%
Zerit		26		26		52		24		76		21		97		19			18			37						-31	%	-29	%	-29	%	-31	%	-31	%	-32	%
Baraclude		—		5		5		2		7		4		11		9			9			18						80	%	*	**	*	**	*	**	*	**	*	**
Infectious Diseases		91		57		148		53		201		75		276		12			(3	)		9						-105	%	-94	%
Cefzil		50		30		80		27		107		46		153		(5	)		(1	)		(6	)					-103	%	-108	%	-95	%	-88	%	-94	%	-88	%
Oncology		115		112		227		131		358		144		502		159			187			346						67	%	52	%
Erbitux		87		97		184		106		290		121		411		136			172			308						77	%	67	%	N/A		N/A		N/A		N/A
Taxol		4		4		8		4		12		5		17		4			4			8						—		—		N/A		N/A		N/A		N/A
Affective (Psychiatric) Disorders		167		206		373		221		594		183		777		237			286			523						39	%	40	%
Abilify**		161		200		361		214		575		175		750		231			267			498						34	%	38	%	21	%	25	%	22	%	25	%
EMSAM		—		—		—		—		—		—		—		—			12			12						—		—		N/A		N/A		N/A		N/A
Immunoscience		—		—		—		—		—		—		—		5			18			23						—		—
Orencia		—		—		—		—		—		—		—		5			18			23						—		—		N/A		N/A		N/A		N/A
Other Pharmaceuticals
Efferalgan		—		—		—		—		—		—		—		—			—			—						—		—		N/A		N/A		N/A		N/A
NUTRITIONALS		255		267		522		266		788		282		1,070		247			282			529						6	%	1	%
Enfamil		162		171		333		168		501		184		685		155			174			329						2	%	-1	%	N/A		N/A		N/A		N/A
Enfagrow		—		—		—		—		—		—		—		—			—			—						—		—		N/A		N/A		N/A		N/A
OTHER HEALTH CARE		242		253		495		252		747		225		972		231			226			457						-11	%	-8	%
CONVATEC		66		71		137		82		219		93		312		73			85			158						20	%	15	%
Ostomy		34		38		72		43		115		46		161		34			41			75						8	%	4	%	N/A		N/A		N/A		N/A
Wound Therapeutics		30		29		59		34		93		40		133		30			34			64						17	%	8	%	N/A		N/A		N/A		N/A
MEDICAL IMAGING		124		127		251		129		380		132		512		158			141			299						11	%	19	%
Cardiolite		91		96		187		95		282		88		370		91			91			182						-5	%	-3	%	N/A		N/A		N/A		N/A
CONSUMER MEDICINES		52		55		107		41		148		—		148		—			—			—						-100	%	-100	%

* This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis.

As a result, the sum of segment sales does not tie to Total Company sales.

** Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

*** In excess of +/- 200%

**** The estimated total U.S. prescription growth for the retail and mail order channels are calculated based on National Prescription Audit (NPA) and Next-Generation Prescription Services (NGPS) data provided by IMS Health, a supplier of market research for the pharmaceutical industry. The NPA data is based on a simple average of the estimated number of prescriptions in the retail and mail order channels, and the NGPS data is based on a weighted average of the estimated number of prescription units (pills) in each of the retail and mail order channels as provided by IMS.

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL* NET SALES FROM CONTINUING OPERATIONS BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2005														2006										% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Total Company	$	2,222	$	2,221	$	4,443	$	2,129	$	6,572	$	2,174	$	8,746	$	2,038	$	2,065	$	4,103					-7	%	-8	%
PHARMACEUTICALS		1,801		1,789		3,590		1,696		5,286		1,778		7,064		1,624		1,654		3,278					-8	%	-9	%
Cardiovascular		632		654		1,286		607		1,893		594		2,487		576		577		1,153					-12	%	-10	%
Plavix		141		145		286		147		433		155		588		136		157		293					8	%	2	%
Pravachol		262		272		534		230		764		218		982		234		195		429					-28	%	-20	%
Avapro/ Avalide		94		101		195		104		299		109		408		94		113		207					12	%	6	%
Coumadin		7		8		15		8		23		6		29		8		9		17					13	%	13	%
Monopril		56		52		108		48		156		43		199		46		48		94					-8	%	-13	%
Virology		199		226		425		201		626		206		832		209		254		463					12	%	9	%
Reyataz		57		85		142		71		213		78		291		88		114		202					34	%	42	%
Sustiva		70		70		140		69		209		68		277		67		78		145					11	%	4	%
Zerit		33		33		66		27		93		26		119		21		23		44					-30	%	-33	%
Baraclude		—		—		—		—		—		1		1		2		5		7					—		—
Infectious Diseases		202		204		406		186		592		211		803		187		175		362					-14	%	-11	%
Cefzil		32		24		56		21		77		29		106		28		24		52					—		-7	%
Oncology		272		259		531		249		780		251		1,031		202		214		416					-17	%	-22	%
Erbitux		—		1		1		1		2		—		2		2		—		2					-100	%	100	%
Taxol		201		182		383		171		554		176		730		143		145		288					-20	%	-25	%
Affective (Psychiatric) Disorders		65		78		143		85		228		84		312		86		90		176					15	%	23	%
Abilify**		27		40		67		46		113		49		162		52		57		109					43	%	63	%
EMSAM		—		—		—		—		—		—		—		—		—		—					—		—
Immunoscience		—		—		—		—		—		—		—		—		—		—					—		—
Orencia		—		—		—		—		—		—		—		—		—		—					—		—
Other Pharmaceuticals
Efferalgan		88		55		143		66		209		74		283		68		62		130					13	%	-9	%
NUTRITIONALS		271		281		552		281		833		302		1,135		318		300		618					7	%	12	%
Enfamil		73		79		152		62		214		93		307		82		79		161					—		6	%
Enfagrow		50		49		99		54		153		53		206		67		59		126					20	%	27	%
OTHER HEALTH CARE		186		202		388		190		578		198		776		180		204		384					1	%	-1	%
CONVATEC		162		176		338		168		506		174		680		157		177		334					1	%	-1	%
Ostomy		93		101		194		96		290		99		389		89		100		189					-1	%	-3	%
Wound Therapeutics		67		74		141		70		211		72		283		68		73		141					-1	%	—
MEDICAL IMAGING		21		24		45		21		66		24		90		23		27		50					13	%	11	%
Cardiolite		11		12		23		11		34		12		46		12		14		26					17	%	13	%
CONSUMER MEDICINES		3		2		5		1		6		—		6		—		—		—					-100	%	-100	%

* This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis.

As a result, the sum of segment sales does not tie to Total Company sales.

** Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

*** In excess of +/- 200%

BRISTOL-MYERS SQUIBB COMPANY

EARNINGS FROM CONTINUING OPERATIONS BEFORE MINORITY INTEREST AND INCOME TAXES

EXCLUDING SPECIFIED ITEMS

($ in millions)

	2006
	Q1			Q2			TOTAL YEAR
Earnings from Continuing Operations Before Minority Interest and Provision for Income Taxes	$	1,193		$	1,110		$	2,303
Specified items:
Gain on sale of product asset		(200	)		—			(200	)
Litigation matters		40			(14	)		26
Insurance recoveries		(21	)		—			(21	)
Provision for restructuring / other		69			24			93
Earnings from Continuing Operations Before Minority Interest and Provision for Income Taxes Excluding Specified Items	$	1,081		$	1,120		$	2,201

	2005
	Q1			Q2			Q3			Q4			TOTAL YEAR
Earnings from Continuing Operations Before Minority Interest	$	928		$	1,130		$	1,626		$	832		$	4,516
and Provision for Income Taxes
Specified items:
Gain on sale of equity investment		(18	)		(9	)		—			—			(27	)
Litigation matters		124			269			—			197			590
Insurance recoveries		—			(295	)		(26	)		—			(321	)
Provision for restructuring / other		68			94			31			95			288
Termination of muraglitizar agreement		—			—			—			(138	)		(138	)
Gain on sale of businesses		—			—			(569	)		—			(569	)
Earnings from Continuing Operations Before Minority Interest and Provision for Income Taxes Excluding Specified Items	$	1,102		$	1,189		$	1,062		$	986		$	4,339

BRISTOL-MYERS SQUIBB COMPANY

DILUTED EARNINGS PER COMMON SHARE FROM CONTINUING OPERATIONS

EXCLUDING SPECIFIED ITEMS

($ in millions)

	2006
	Q1			Q2		TOTAL YEAR *
Diluted Earnings per Common Share from Continuing Operations	$	0.36		$	0.34	$	0.70
Specified items:
Gain on sale of product asset		(0.06	)		—		(0.06	)
Litigation matters		0.01			—		0.01
Insurance recoveries		(0.01	)		—		(0.01	)
Provision for restructuring / other		0.02			0.01		0.03
Diluted Earnings per Common Share from Continuing Operations Excluding Specified Items	$	0.32		$	0.35	$	0.67

	2005
	Q1			Q2			Q3			Q4			TOTAL YEAR *
Diluted Earnings per Common Share from Continuing Operations	$	0.27		$	0.50		$	0.49		$	0.26		$	1.52
Specified items:
Gain on sale of equity investment		(0.01	)		—			—			—			(0.01	)
Litigation matters		0.05			0.10			—			0.06			0.22
Insurance recoveries		—			(0.09	)		(0.01	)		—			(0.10	)
Provision for restructuring / other		0.03			0.03			0.02			0.03			0.10
Termination of muraglitizar agreement		—			—			—			(0.04	)		(0.04	)
Gain on sale of businesses		—			—			(0.19	)		—			(0.19	)
Tax items		—			(0.07	)		—			—			(0.07	)
Diluted Earnings per Common Share from Continuing Operations Excluding Specified Items	$	0.34		$	0.47		$	0.31		$	0.31		$	1.43

* quarterly amounts may not add to the annual total due to rounding of individual calculations.

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE THREE MONTHS ENDED JUNE 30, 2006 AND 2005

($ in millions)

Three months ended June 30, 2006

	Cost of products sold		Research and development		Provision for restructuring, net		Litigation income			Total
Litigation Matters:
Commercial litigation	$	—	$	—	$	—	$	(14	)	$	(14	)
Other:
Accelerated depreciation		20		1		—		—			21
Downsizing and streamlining of worldwide operations		—		—		3		—			3
	$	20	$	1	$	3	$	(14	)		10
Income taxes on items above											3
Reduction to Net Earnings from Continuing Operations										$	13

Three months ended June 30, 2005

	Cost of products sold		Research and development		Provision for restructuring, net		Litigation (income)/ charges, net			Other (income)/ expense, net			Total
Litigation Matters:
Private litigations and governmental investigations	$	—	$	—	$	—	$	249		$	—		$	249
ERISA litigation and other matters		—		—		—		20			—			20
Insurance recoveries		—		—		—		(295	)		—			(295	)
		—		—		—		(26	)		—			(26	)
Other:
Gain on sale of equity investment		—		—		—		—			(9	)		(9	)
Loss on sale of fixed assets		—		—		—		—			1			1
Accelerated depreciation and asset impairment		21		1		—		—			—			22
Downsizing and streamlining of worldwide operations		—		—		2		—			—			2
Debt retirement costs		—		—		—		—			69			69
	$	21	$	1	$	2	$	(26	)	$	61			59
Income taxes on items above														18
Adjustment to taxes on repatriation of foreign earnings														(135	)
Increase to Net Earnings from Continuing Operations													$	(58	)

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE SIX MONTHS ENDED JUNE 30, 2006 AND 2005

($ in millions)

Six months ended June 30, 2006

	Cost of products sold		Research and development		Marketing selling and administrative		Provision for restructuring, net		Litigation income			Other (income)/ expense, net		Gain on sale of product asset			Total
Litigation Matters:
Insurance recovery	$	—	$	—	$	—	$	—	$	(21	)	$	—	$	—		$	(21	)
Commercial litigations		—		—		—		—		(14	)		40		—			26
		—		—		—		—		(35	)		40		—			5
Other:
Accelerated depreciation, asset impairment and contract termination		66		1		4		—		—			—		—			71
Downsizing and streamlining of worldwide operations		—		—		—		4		—			—		—			4
Upfront and milestone payments		—		18		—		—		—			—		—			18
Gain on sale of product asset		—		—		—		—		—			—		(200	)		(200	)
	$	66	$	19	$	4	$	4	$	(35	)	$	40	$	(200	)		(102	)
Income taxes on items above																		52
Minority interest, net of taxes																		(13	)
Increase to Net Earnings from Continuing Operations																	$	(63	)

Six months ended June 30, 2006

	Cost of products sold		Research and development		Provision for restructuring, net		Litigation (income) /charges, net			Other (income)/ expense, net			Total
Litigation Matters:
Private litigations and governmental investigations	$	—	$	—	$	—	$	373		$	—		$	373
ERISA liability and other matters		—		—		—		20			—			20
Insurance recoveries		—		—		—		(295	)		—			(295	)
		—		—		—		98			—			98
Other:
Gain on sale of equity investment		—		—		—		—			(27	)		(27	)
Loss on sale of fixed assets		—		—		—		—			17			17
Accelerated depreciation and asset impairment		34		2		—		—			—			36
Downsizing and streamlining of worldwide operations		—		—		5		—			—			5
Upfront and milestone payments		—		35		—		—			—			35
Debt retirement costs		—		—		—		—			69			69
	$	34	$	37	$	5	$	98		$	59			233
Income taxes on items above														(24	)
Adjustment to taxes on repatriation of foreign earnings														(135	)
Reduction to Net Earnings from Continuing Operations													$	74

BRISTOL-MYERS SQUIBB COMPANY

SELECT BALANCE SHEET INFORMATION

($ in millions)

	March 31, 2005		June 30, 2005		September 30, 2005		December 31, 2005		March 31, 2006		June 30, 2006		September 30, 2006		December 31, 2006
Cash, cash equivalents and marketable debt securities	$	5,982	$	3,040	$	3,781	$	5,799	$	5,281	$	5,357	$	—	$	—
Receivables, net of allowances		3,647		3,315		3,305		3,378		3,236		3,326		—		—
Short-term borrowings		244		292		277		231		234		189		—		—
Long-term debt		8,326		6,008		5,895		8,364		8,278		8,239		—		—
Stockholders’ equity		10,381		10,801		11,268		11,208		11,556		11,712		—		—
Capital expenditures and capitalized software (for the quarter ended)		181		171		185		201		202		160		—		—

BRISTOL-MYERS SQUIBB COMPANY

2006 DILUTED EPS FROM CONTINUING OPERATIONS

IMPACT OF PROJECTED SPECIFIED ITEMS

	Diluted EPS Impact
Downsizing and streamlining of worldwide operations	$	0.04
Licensing and milestone payments		0.02
Gain on sale of product asset		(0.06	)
Litigation matters		0.01
Insurance recoveries		(0.01	)
Total	$	—

BRISTOL-MYERS SQUIBB COMPANY

ESTIMATED MONTHS ON HAND OF TOP 15 U.S. PHARMACEUTICAL PRODUCTS

IN THE U.S. WHOLESALER DISTRIBUTION CHANNEL

The following table sets forth, for each of the Company’s top 15 pharmaceutical products (based on 2005 annual net sales) and other products that the Company views as current and future growth drivers sold by the Company’s U.S. Pharmaceuticals business, the U.S. Pharmaceuticals net sales and the estimated number of months on hand of the applicable product in the U.S. wholesaler distribution channel for each of the quarters ended June 30, 2006 and 2005 and March 31, 2006 and 2005.

	June 30, 2006				March 31, 2006				June 30, 2005				March 31, 2005
	Net Sales			Months on Hand	Net Sales			Months on Hand	Net Sales			Months on Hand	Net Sales		Months on Hand
	(Dollars in Millions)				(Dollars in Millions)				(Dollars in Millions)				(Dollars in Millions)
Abilify (total revenue)	$	267		0.5	$	231		0.5	$	200		0.7	$	161	0.7
Avapro/Avalide		167		0.5		139		0.4		157		0.6		102	0.8
Baraclude		9		0.7		9		1.0		5		4.7		—	—
Cefzil		(1	)	25.7		(5	)	9.8		30		0.8		50	0.7
Coumadin		46		0.8		47		0.6		42		0.7		42	1.0
Erbitux*		172		—		136		—		97		—		87	#
Glucophage Franchise		22		0.6		25		0.7		44		0.8		39	1.0
Kenalog		22		0.8		23		0.7		15		0.5		11	0.9
Orencia		18		0.3		5		0.9		—		—		—	—
Paraplatin		2		1.7		7		1.2		(1	)	0.8		15	0.9
Plavix		988		0.5		850		0.4		823		0.6		673	0.8
Pravachol		128		1.0		302		0.4		353		0.7		258	0.8
Reyataz		122		0.6		119		0.6		98		0.8		92	0.8
Sustiva		115		0.5		108		0.5		97		0.8		103	0.8
Tequin		(6	)	2.7		13		0.8		22		0.8		38	0.7
Videx/Videx EC		5		0.9		4		0.9		5		1.0		10	1.2
Zerit		18		0.7		19		0.7		26		0.8		26	0.8

For all products other than Erbitux, the Company determines the above months on hand estimates by dividing the estimated amount of the product in the U.S. wholesaler distribution channel by the estimated amount of out-movement of the product from the U.S. wholesaler distribution channel over a period of 31 days, all calculated as described below. Factors that may influence the Company’s estimates include generic competition, seasonality of products, wholesaler purchases in light of increases in wholesaler list prices, new product launches, new warehouse openings by wholesalers and new customer stockings by wholesalers. In addition, such estimates are calculated using third party data, which represent their own record-keeping processes and as such, may also reflect estimates.

Estimates of product in the wholesaler distribution channel and out-movement are based on weekly information received directly from third-parties, and excludes any inventory held by intermediaries such as retailers and hospitals, and excludes goods in transit to such wholesalers. The Company determines the amount of out-movement of a product over a period of 31 days by using the most recent out-movement of a product as provided by these third parties, adjusted to reflect the Company’s estimate of goods in transit to these wholesalers. The Company estimates the amount of goods in transit by using information provided by these wholesalers with respect to their open orders and the Company’s records of sales to these wholesalers with respect to such open orders.

* To help maintain the product quality of the Company’s biologic oncology product, Erbitux, the product is shipped only to end-users and not to other intermediaries (such as wholesalers) to hold for later sales. During 2004 and through May 2005, one of the Company’s wholesalers provided warehousing, packing and shipping services for Erbitux. Such wholesaler held Erbitux inventory on consignment and, under the Company’s revenue recognition policy, the Company recognized revenue when such inventory was shipped by the wholesaler to the end-user. The above estimates of months on hand for the three months ended March 31, 2005, were calculated by dividing the inventories of Erbitux held by the wholesaler for its own account as reported by the wholesaler as of the end of the quarter by the Company’s net sales for the last calendar month of the quarter. The inventory levels reported by the wholesaler are a product of the wholesaler’s own record-keeping process. Upon the divestiture of OTN in May 2005, the Company discontinued the consignment arrangement with the wholesaler, and thereafter did not have Erbitux consignment inventory. Following the divesture, the Company sells Erbitux to intermediaries (such as specialty oncology distributors) and ships Erbitux directly to the end users of product who are the customers of those intermediaries. The company recognizes revenue upon such shipment consistent with its revenue recognition policy. Accordingly, subsequent to June 30, 2005, there was no Erbitux inventory held by wholesalers.

# Less than 0.1 months on hand.

BRISTOL-MYERS SQUIBB COMPANY

ESTIMATED MONTHS ON HAND OF TOP INTERNATIONAL PHARMACEUTICAL

AND WORLDWIDE NON-PHARMACEUTICAL PRODUCTS

The following table, which was posted on the Company’s website and furnished on Form 8-K/A on May 31, 2006, sets forth for each of the Company’s key products sold by the reporting segments listed below, the net sales of the applicable product for each of the quarters ended March 31, 2006, December 31, 2005 and March 31, 2005 and the estimated number of months on hand of the applicable product in the direct customer distribution channel for the reporting segment as of the end of each of the three quarters. The estimates of months on hand for key products described below for the International Pharmaceuticals reporting segment are based on data collected for all of the Company’s significant business units outside of the United States. For the other reporting segments, estimates are based on data collected for the United States and all significant business units outside of the United States.

	March 31, 2006			December 31, 2005			March 31, 2005
	Net Sales		Months on Hand	Net Sales		Months on Hand	Net Sales		Months on Hand
	(Dollars in Millions)			(Dollars in Millions)			(Dollars in Millions)
International Pharmaceuticals
Abilify (total revenue)	$	52	0.6	$	49	0.6	$	27	0.6
Avapro/Avalide		94	0.5		109	0.6		94	0.4
Baraclude		2	1.1		1	—		—	—
Bufferin		22	0.6		36	0.7		26	0.5
Capoten		35	0.8		38	0.8		42	0.8
Dafalgan		37	1.4		34	1.2		40	1.3
Efferalgan		68	1.2		74	1.0		88	0.9
Maxipime		40	0.8		48	0.8		46	0.7
Monopril		46	1.1		43	0.9		56	0.6
Paraplatin		26	0.6		33	0.8		29	0.6
Perfalgan		46	0.6		43	0.6		42	0.5
Plavix		136	0.5		155	0.6		141	0.7
Pravachol		234	1.5		218	0.8		262	0.7
Reyataz		88	0.6		78	0.6		57	0.6
Sustiva		67	0.5		68	0.6		70	0.5
Taxol		143	0.6		176	0.8		201	0.5
Videx/Videx EC		31	0.8		34	0.9		39	0.8
Nutritionals
Enfamil/Enfagrow		304	0.9		330	1.0		285	0.9
Nutramigen		48	1.0		48	1.1		44	1.0
Other Health Care
ConvaTec
Ostomy		123	0.9		145	1.0		127	0.9
Wound Therapeutics		98	0.8		112	0.9		97	0.8
Medical Imaging
Cardiolite		103	0.7		100	1.0		102	0.7

The above months on hand information represents the Company’s estimates of aggregate product level inventory on hand at direct customers divided by the expected demand for the applicable product. Expected demand is the estimated ultimate patient/consumer demand calculated based on estimated end-user consumption or direct customer out-movement data over the most recent 31 day period or other reasonable period. Factors that may affect the Company’s estimates include generic competition, seasonality of products, direct customer purchases in light of price increases, new product or product presentation launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations.